Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

OTHER 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Renal Insufficiency 1Osteosarcoma 1Neoplasms 1Lymphoma 1Leukemia 1

Interventions

Ifosfamide 30Methotrexate 29Doxorubicin 26Cyclophosphamide 24Cisplatin 22Filgrastim 18Etoposide 17Gemcitabine 16Leucovorin 14Magnetic Resonance Spectroscopy 11Temozolomide 10Specimen Handling 10cabozantinib 9apatinib 9X-Rays 9Carboplatin 9fludarabine 8Radiotherapy 8Nivolumab 8Neoadjuvant Therapy 8Irinotecan 8Granulocyte Colony-Stimulating Factor 8Drug Therapy 8Docetaxel 8Zoledronic Acid 7Vincristine 7Sirolimus 7Phantoms, Imaging 7Biopsy 7mifamurtide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × Carboxypeptidases × Clear all
NCT00481559 2014-01-17

Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity

BTG International Inc.

Approved for marketing
LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neoplasms, Osteosarcoma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡